● Recruiting

A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies

Condition: Cancer · Sponsor: Canadian Cancer Trials Group

PhasePhase 2

Planned participants60

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

I238A: The purpose of this study is to find out what effects being treated with durvalumab has on cancer. The researchers doing this study also want to evaluate if prednisone (a type of steroid), when given together with durvalumab, can reduce any side effects. I238B: The purpose of this study is to allow patients previously enrolled on a completed CCTG trial to continue treatment with durvalumab (+/- tremelimumab)

This description comes directly from the study's public registry record.

Talk to the study team

Pierre-Olivier Gaudreau · 613-533-6430 · p-ogaudreau@ctg.queensu.ca

Always discuss trial participation with your own doctor first.

Locations (11)

Cross Cancer Institute	Edmonton, Alberta, Canada	Recruiting
BCCA - Kelowna	Kelowna, British Columbia, Canada	Recruiting
BCCA - Vancouver	Vancouver, British Columbia, Canada	Recruiting
Regional Health Authority B, Zone 2	Saint John, New Brunswick, Canada	Recruiting
Juravinski Cancer Centre at Hamilton Health Sciences	Hamilton, Ontario, Canada	Recruiting
Waterloo Regional Health Network (WRHN)	Kitchener, Ontario, Canada	Recruiting
Ottawa Hospital Research Institute	Ottawa, Ontario, Canada	Recruiting
University Health Network	Toronto, Ontario, Canada	Recruiting
Windsor Regional Cancer Centre	Windsor, Ontario, Canada	Recruiting
CHUM-Centre Hospitalier de l'Universite de Montreal	Montreal, Quebec, Canada	Recruiting
Saskatoon Cancer Centre	Saskatoon, Saskatchewan, Canada	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03847649